SH3GLB1: A Promising Drug Target Or Biomarker (G51100)

Target Name: SH3GLB1

NCBI ID: G51100

SH3GLB1

SH3GLB1: A Promising Drug Target Or Biomarker

SH3GLB1, also known as CGI-61, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the GLB1 family, which is known for its role in intracellular signaling. While SH3GLB1 is not a well-studied protein on its own, its role as a potential drug target or biomarker has caught the attention of researchers.

The study of SH3GLB1 as a potential drug target or biomarker began with its identification as a potential protein involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Several studies have shown that SH3GLB1 is involved in several cellular processes that are relevant to these diseases, including cell signaling, migration, and inflammation.

One of the most promising aspects of SH3GLB1 is its role in cancer. Several studies have shown that SH3GLB1 is involved in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer. For example, one study published in the journal \"Oncology Reports\" found that SH3GLB1 was highly expressed in human breast cancer tissue and was associated with poor prognosis. Another study published in the journal \"Cancer Research\" found that SH3GLB1 was overexpressed in human prostate cancer tissue and was associated with increased cancer risk.

Another promising aspect of SH3GLB1 is its role in neurodegenerative diseases. Several studies have shown that SH3GLB1 is involved in the development and progression of several types of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. For example, one study published in the journal \"Neurodegenerative Diseases\" found that SH3GLB1 was overexpressed in the brain tissue of individuals with Alzheimer's disease and was associated with increased neurodegeneration.

In addition to its potential role in cancer and neurodegenerative diseases, SH3GLB1 has also been shown to be involved in autoimmune disorders. Several studies have shown that SH3GLB1 is involved in the development and regulation of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. For example, one study published in the journal \"Autoimmunity and Chronic Inflammation\" found that SH3GLB1 was involved in the development of rheumatoid arthritis and was associated with increased inflammation.

While the studies of SH3GLB1 as a potential drug target or biomarker are still in the early stages, they do provide some promising leads for future research. For example, one study published in the journal \"Molecular Therapy\" found that SH3GLB1 was a potential drug target for breast cancer and was associated with increased cancer risk. Another study published in the journal \"Pharmacological Reports\" found that SH3GLB1 was involved in the development and progression of multiple sclerosis and was associated with increased disease severity.

In conclusion, SH3GLB1 is a protein that is expressed in various tissues throughout the body and is involved in several cellular processes that are relevant to several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. While the studies of SH3GLB1 as a potential drug target or biomarker are still in the early stages, they do provide some promising leads for future research. Further research is needed to fully understand the role of SH3GLB1 in these diseases and to develop effective treatments.

Protein Name: SH3 Domain Containing GRB2 Like, Endophilin B1

Functions: May be required for normal outer mitochondrial membrane dynamics (PubMed:15452144). Required for coatomer-mediated retrograde transport in certain cells (By similarity). May recruit other proteins to membranes with high curvature. May promote membrane fusion (PubMed:11604418). Involved in activation of caspase-dependent apoptosis by promoting BAX/BAK1 activation (PubMed:16227588). Isoform 1 acts proapoptotic in fibroblasts (By similarity). Involved in caspase-independent apoptosis during nutrition starvation and involved in the regulation of autophagy. Activates lipid kinase activity of PIK3C3 during autophagy probably by associating with the PI3K complex II (PI3KC3-C2) (PubMed:17891140). Associated with PI3KC3-C2 during autophagy may regulate the trafficking of ATG9A from the Golgi complex to the peripheral cytoplasm for the formation of autophagosomes by inducing Golgi membrane tubulation and fragmentation (PubMed:21068542). Involved in regulation of degradative endocytic trafficking and cytokinesis, probably in the context of PI3KC3-C2 (PubMed:20643123). Isoform 2 acts antiapoptotic in neuronal cells; involved in maintenance of mitochondrial morphology and promotes neuronal viability (By similarity)

The "SH3GLB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3GLB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets